Connect with us

バイオテクノロジー

Training The Immune System To Attack Cancer With Probiotics

mm
Securities.io maintains rigorous editorial standards and may receive compensation from reviewed links. We are not a registered investment adviser and this is not investment advice. Please view our affiliate disclosure.

Novel Immunotherapy

Most modern cancer therapies aim to train the body’s immune system to detect and attack cancer cells efficiently. This method even won the 2018 Nobel Prize in Medicine (see the link for more information).

It can be done with now-established therapies like CAR-T therapies or maybe soon experimental treatments like mRNA vaccines against specific cancers, which are making quick progress with clinical trials for mRNA against lung cancer.

However, this is not the only possible way to encourage the immune system to target cancer cells. Researchers at Columbia University, New York, have modified bacteria to attack cancer. They published their findings in the prestigious publication Nature under the title “Probiotic neoantigen delivery vectors for precision cancer immunotherapy.”

Using Bacteria Against Cancer

The idea is not new; in the 19th century, it was noticed that injecting bacteria into a tumor could cause it to shrink. Today, early-stage bladder cancers are treated with bacteria. The mechanism behind it is that bacteria can prosper in the oxygen-deprived environment of tumors and locally provoke an immune response that attacks both the bacteria and the cancer cells.

The issue is that such an undirected process is often not enough to help with cancer therapy. So, the bacteria have to be modified for maximum efficiency.

Customizing Bacteria For Cancer Detection

The central concept is to make the bacteria express markers specific to cancer cells. These “neoantigens” are proteins that cancer cells produce but normal cells do not.

By having the bacteria carrying these proteins, the immune systems detect them and start attacking anything carrying them, both bacteria and cancer cells.

This has a solid advantage over the type of immunotherapy, as the bacteria-induced reactions activate a wide variety of different immune cells. So it involves NK cells, lymphocytes CD4+ and CD8+, macrophages, antigen-presenting cells (APC), etc.

Reducing Immunity Suppression

Jonathanは元バイオケミストの研究者で、遺伝子分析と臨床試験に従事していました。現在は、株式アナリストおよびファイナンスライターとして、革新、市場サイクル、地政学に焦点を当てた出版物 'The Eurasian Century" に貢献しています。

Advertiser Disclosure: Securities.io is committed to rigorous editorial standards to provide our readers with accurate reviews and ratings. We may receive compensation when you click on links to products we reviewed. ESMA: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Investment advice disclaimer: The information contained on this website is provided for educational purposes, and does not constitute investment advice. Trading Risk Disclaimer: There is a very high degree of risk involved in trading securities. Trading in any type of financial product including forex, CFDs, stocks, and cryptocurrencies. This risk is higher with Cryptocurrencies due to markets being decentralized and non-regulated. You should be aware that you may lose a significant portion of your portfolio. Securities.io is not a registered broker, analyst, or investment advisor.